The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Gaudio, Eugenio [1 ]
Cascione, Luciano [1 ]
Ponzoni, Maurilio [2 ]
Tarantelli, Chiara [1 ]
Bernasconi, Elena [1 ]
Riveiro, Maria Eugenia [3 ]
Cvitkovic, Esteban [3 ]
Zucca, Emanuele [4 ]
Bertoni, Francesco [1 ]
机构：
[1] IOR Inst Oncol Res, Lymphoma & Genom Res Program, Bellinzona, Switzerland
[2] Ist Sci San Raffaele, Unit Lymphoid Malignancies, Milan, Italy
[3] Oncol Therapeut Dev, Clichy, France
[4] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 37 条
  • [21] Selinexor (KTP-330)-a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)
    Ben-Barouch, Sharon
    Kuruvilla, John
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (01) : 15 - 21
  • [22] Activity and tolerability of combination of venetoclax with the Aurora kinase B Inhibitor AZD2811 in preclinical diffuse large B-cell lymphoma models
    Cheraghchi-Bashi, Azadeh
    Willis, Brandon
    Mongeon, Kevin
    Gordon, Jacob
    Bulusu, Krishna
    Coker, Elizabeth
    Jaaks, Patricia
    Garnett, Mathew
    Mettetal, Jerome
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [23] Targeted MCL-1 inhibition to induce cell death and synergize with conventional chemotherapeutic agents in diffuse large B-cell lymphoma (DLBCL) pre-clinical models
    Ferdman, Robert Zachary
    Gu, Jenny
    Mavis, Cory
    Torka, Pallawi
    Hernandez-Ilizaliturri, Francisco J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] ARQ 531, a potent reversible BTK inhibitor, exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma
    Eathiraj, Sudharshan
    Yu, Yi
    Savage, Ron
    Woyach, Jennifer A.
    Reiff, Sean D.
    Johnson, Amy J.
    Schwartz, Brian
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [25] Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)
    Karkhanis, Vrajesh
    Fiskus, Warren
    Mill, Christopher Peter
    Maiti, Abhishek
    Lara, Bernardo H.
    Maher, James V.
    Bhalla, Isean
    Shao, Nancy
    Green, Michael R.
    Khoury, Joseph D.
    Bhalla, Kapil N.
    [J]. BLOOD, 2019, 134
  • [26] JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)
    Gu, Juan J.
    Barth, Matthew J.
    Zhang, Qunling
    Mavis, Cory
    Hernandez-Ilizaliturri, Francisco J.
    [J]. BLOOD, 2016, 128 (22)
  • [27] Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma
    Recasens-Zorzo, Clara
    Cardesa-Salzmann, Teresa
    Ros-Blanco, Laia
    Esteve-Arenys, Anna
    Clot, Guillem
    Guerrero-Hernandez, Martina
    Valera, Alejandra
    Moros, Alejandra
    Gutierrez, Gonzalo
    Casanova, Isolda
    Mangues, Ramon
    Sanjuan, Alejandra
    Menendez, Pablo
    Rodriguez, Vanina
    Martinez, Antonio
    Jares, Pedro
    Colomer, Dolors
    Teixido, Jordi
    Borrell, Jose Ignacio
    Campo, Elias
    Lopez-Guillermo, Armando
    Colomo, Luis
    Perez-Galan, Patricia
    Roue, Gael
    [J]. CANCER RESEARCH, 2017, 77
  • [28] Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Hamlin, Paul A.
    Musteata, Vasile
    Zodelava, Mamia
    Park, Steven I.
    Burnett, Christine
    Dabovic, Kristina
    Williams, Eric T.
    Higgins, Jack P.
    Persky, Daniel O.
    [J]. BLOOD, 2019, 134
  • [29] Tyrosine Kinase Inhibitor Si409 Has In Vitro and In Vivo Anti-Tumor Activity Against Diffuse Large B-Cell Lymphoma
    Enrico Rango
    Salvatore Di Maria
    Claudio Zamperini
    Federica Poggialini
    Emmanuele Crespan
    Cecilia Perini
    Samantha Sabetta
    Simona Saponara
    Fabio Fusi
    Giovanni Maga
    Adriano Angelucci
    Eugenio Gaudio
    Francesco Berton
    Silvia Schenone
    Lorenzo Botta
    Elena Dreassi
    Maurizio Botta
    [J]. Pharmaceutical Chemistry Journal, 2023, 56 : 1616 - 1626
  • [30] Tyrosine Kinase Inhibitor Si409 Has In Vitro and In Vivo Anti-Tumor Activity Against Diffuse Large B-Cell Lymphoma
    Rango, Enrico
    Di Maria, Salvatore
    Zamperini, Claudio
    Poggialini, Federica
    Crespan, Emmanuele
    Perini, Cecilia
    Sabetta, Samantha
    Saponara, Simona
    Fusi, Fabio
    Maga, Giovanni
    Angelucci, Adriano
    Gaudio, Eugenio
    Berton, Francesco
    Schenone, Silvia
    Botta, Lorenzo
    Dreassi, Elena
    Botta, Maurizio
    [J]. PHARMACEUTICAL CHEMISTRY JOURNAL, 2023, 56 (12) : 1616 - 1626
1234